Andreas Kjaer - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Andreas Kjaer's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Andreas Kjaer
Verified
Editor-in-Chief, Diagnostics
Copenhagen
Beats
Mattress Reviews , Sleep , Sleep Accessories , Food
Content
Phase II study of uPAR-PET/CT for staging of primary breast cancer in comparison with ultrasound and fine needle biopsies - Scientific Reports
By Andreas Kjaer| Nature Verified AbstractAccurate initial staging of patients with breast cancer is essential for planning optimal treatment strategies. However, currently, no imaging modality is able to detect lymph node metastases preoperatively with sufficient reliability; therefore, the N status depends on the sentinel node procedure for ~ 70% of patients.
By Andreas Kjaer| MDPI@ All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Phase II study of uPAR-PET/CT for staging of primary breast cancer in comparison with ultrasound and fine needle biopsies - Scientific Reports
By Andreas Kjaer| Nature Verified AbstractAccurate initial staging of patients with breast cancer is essential for planning optimal treatment strategies. However, currently, no imaging modality is able to detect lymph node metastases preoperatively with sufficient reliability; therefore, the N status depends on the sentinel node procedure for ~ 70% of patients.
Company Info
Diagnostics
Quest Diagnostics is a prominent provider of diagnostic information services, established in 1967 in New York City. Headquartered in Madison, New Jersey, the company is publicly traded and is part of the S&P 500. It has evolved from a small operation into a global leader in the diagnostic field through strategic acquisitions and technological advancements. The company offers a wide range of diagnostic services, including routine and specialized testing such as blood tests, genetic testing, and anatomical pathology. It also provides COVID-19 testing and consumer-initiated testing through QuestDirect, allowing patients to order lab tests directly. Quest Diagnostics serves a significant portion of the U.S. population, including one in three adult Americans, and collaborates with employers and health plans to enhance workplace wellness and population health analytics. With nearly 50,000 employees, Quest Diagnostics is dedicated to improving healthcare decisions through data-driven insights.
'+1 800-222-0446
Founded: 1967